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The present study aimed at evaluating whether a weekly cisplatin, epirubicin, and paclitaxel (PET) regimen could increase the
pathological complete response (pCR) rate in comparison with a tri-weekly epirubicin and paclitaxel administration in locally
advanced breast cancer (LABC) patients. Patients with stage IIIB disease were randomised to receive either 12 weekly cycles of
cisplatin 30mgm
 2, epirubicin 50mgm
 2, and paclitaxel 120mgm
 2 (PET) plus granulocyte-colony stimulating factor support, or
four cycles of epirubicin 90mgm
 2þpaclitaxel 175mgm
 2 (ET) every 3 weeks. Overall, 200 patients (PET/ET¼100/100) were
included in this study. A pCR in both breast and axilla occurred in 16 (16%) PET patients and in six (6%) ET patients (P¼0.02). The
higher activity of PET was evident only in ER negative (27.5 vs 5.4%; P¼0.026), and in HER/neu positive (31 vs 5%; P¼0.037)
tumours. The two arms yielded similar pCR rate in ER positive (PET/ET¼7.5/7.1%) and HER/neu negative (PET/ET¼10/6%)
patients. At a 39 months median follow-up, 70 patients showed a progression or relapses (PET, 32 vs ET, 38). Anaemia, mucositis,
peripheral neuropathy, and gastrointestinal toxicity were substantially more frequent in the PET arm. The PET weekly regimen is
superior to ET in terms of pCR rate in LABC patients with ER negative and/or HER2 positive tumours Mature data in terms of
disease-free and overall survival are needed to ascertain whether this approach could improve the prognosis of these subsets of
LABC patients.
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The role of chemotherapy in improving the prognosis of
locally advanced breast cancer (LABC) patients is widely
recognised. High objective response rates can be achieved
with standard combination chemotherapy, rendering in most
cases the tumour operable at the end of the treatment (Hortobagyi
and Buzdar, 1997). Primary chemotherapy is also becoming
very popular in patients with operable disease at diagnosis,
since it permits a substantial increase in the rate of breast-sparing
surgery, and allows an early pathological evaluation of the effect of
treatment. The absence of residual tumour in both breast
and axilla is associated with a much lower risk of relapse (Chollet
et al, 2002; Faneyete et al, 2003). Unfortunately, the chance of
achieving such a goal in women with LABC is low. Indeed, in the
NSABP-B18 trial, the pCR rate after primary chemotherapy was
o3% in women with T3 (operable) disease (Fisher et al, 1997).
During the last decade, several new drugs with different
mechanisms of action have been introduced into clinical practice.
Among them, the taxanes (paclitaxel and docetaxel) have raised
great enthusiasm, and have been rapidly incorporated in
combination regimens (Dombernowsky et al, 1996; Moliterni
et al, 1997).
Phase III trials comparing taxane- vs non taxane-including
regimens, have been carried out in breast cancer patients with
loco-regional disease. Both in the NSABP-B27 (Bear et al, 2003)
and in the Aberdeen (Smith et al, 2002) studies, the addition of
docetaxel resulted in a two-times greater pCR rate in comparison
with the standard arm. Notably, a substantial proportion of
patients in the Aberdeen trial had LABC. French investigators
(Dieras et al, 2004) reported a significantly higher pCR rate with
primary doxorubicin plus paclitaxel in comparison with a standard
doxorubicin plus cyclophosphamide regimen.
A better therapeutic index has been recently hypothesised for
the weekly paclitaxel administration. In an MDACC trial (Green
et al, 2005), 258 patients with operable disease were randomised to
receive either weekly or every 3 weeks paclitaxel followed by four
FAC (5-fluorouracil, doxorubicin and cyclophosphamide cycles
before surgery. The pCR rate in the weekly arm was twice that of
the tri-weekly arm (28.8 vs 13.6%).
In the last few years, increasing interest has arisen about the
role of platinum compounds in the treatment of breast cancer
patients. Several cisplatin-based regimens have been tested in the
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sneo-adjuvant setting, showing high anti tumour activity (Orlando
et al, 2001; Ezzat et al, 2004). In the mid-nineties, we started the
assessment of a weekly triplet regimen including cisplatin,
epirubicin, and paclitaxel (PET regimen) in breast cancer patients
(Frasci et al, 1999). This weekly approach was initially tested in a
phase II study in women with LABC (Frasci et al, 2000). The
promising activity data we observed (overall response rate, 90%,
and pCR rate, 12%) prompted us to start the present phase III trial,
which aimed at comparing this regimen with a tri-weekly
epirubicin plus paclitaxel administration.
METHODS
Eligibility criteria
Patients with histological proven locally advanced (T4 a-d and/or
N2 fixed to other structures) breast cancer with no prior
chemotherapy were eligible. Other selection criteria were: age
o75, ECOG performance status p2, adequate bone marrow (ANC
X2.0 10
9l
 1, platelet count X100 10
9l
 1, and haemoglobin
level X100gl
 1), liver (bilirubin level o1.5 the upper normal limit
[UNL], AST and/or ALT o3 UNL, prothrombin time o1.5 times
control), renal (creatinine clearance X60mlmin
 1) and cardiac
functions (left ventricular ejection fraction 450%, absence of
severe cardiac arrhythmia or heart failure, second- or third-degree
heart block or acute myocardial infarction within 4 months prior
to study entry). Previous or concurrent malignancy, were also
considered as exclusion criteria, except for inactive nonmelanoma
skin cancer, and in situ carcinoma of the cervix. All patients gave
their written informed consent, and the trial was approved by the
Independent Ethical Committee of the National Tumour Institute
of Naples.
Pretreatment evaluation
Within 4 weeks before starting chemotherapy, all patients under-
went the following studies: complete history and physical
examination, ECG and bi-dimensional echocardiography, mam-
mography, chest X-ray, liver ultrasonography, radionuclide bone
scan (with X-ray evaluation of suspicious bone segments), and CT
or MRI of the brain in the case of suspected brain involvement.
Laboratory investigation included a complete blood cell count with
white blood cell (WBC) differential and platelet count, BUN,
creatinine, bilirubin, SGOT, alkaline phosphatase, lactate dehy-
drogenase, prothrombin time, partial thromboplastin and throm-
bin time, urinalysis. A core biopsy of the primary tumour was also
performed with the immunohistochemical assessment of the main
prognostic variables (steroid hormones receptors, Ki67, HER2/
neu). The HER2/neu was measured by using the monoclonal
antibodies Mab 1 and CB11 on 3mm sections of paraffin-embedded
tumour samples.
Treatment
All eligible patients were randomly allocated to receive: (arm A)
epirubicin 50mgm
 2 as an i.v. bolus, followed by paclitaxel
120mgm
 2 as a 1-h infusion, and cisplatin 30mgm
 2 as a 30min
infusion, weekly for a maximum of 12 cycles. Recombinant human
G-CSF 300mgday
 1 was also given subcutaneously on days 3–5 of
each week. Short-term forced hyperhydration (1l of saline over
2h), and prophylaxis for nausea/vomiting (HT3 receptor antago-
nists) were also performed. Prophylaxis for hypersensitivity
reactions consisted of dexamethasone 8mg i.v. and promethazine
50mg i.m. plus ranitidine 50mg i.v. 30min before paclitaxel
administration; or (arm B) epirubicin 90mgm
 2 as an i.v. bolus,
followed by paclitaxel 175mgm
 2 as a 1-h infusion, every 3 weeks
for a maximum of four cycles. The same antiemetic and anti-
hypersensitivity procedures adopted for arm A were performed.
Within 4 weeks from the end of chemotherapy patients
underwent surgery. Breast sparing surgery was performed when-
ever feasible. It consisted of quadrantectomy together with
standard level I and II axillary lymph-node dissection.
Four cycles of CMF were delivered after surgery, in patients
whose pathologic assessment showed less than four involved
axillary lymph nodes; whereas four FEC (epirubicin 60mgm
 2
instead of methotrexate) cycles were administered in those women
showing four or more involved axillary nodes. On completion of
postoperative chemotherapy, radiotherapy was performed on all
patients who underwent conservative surgery, and to those who
underwent mastectomy and had more than three axillary nodes
involved, muscle, skin and/or nipple involvement, or had G3
tumour at diagnosis.
Hormone treatment was also given on completion of post-
operative chemotherapy. LH-RH analogue for 2 years together
with tamoxifen for 5 years was administered in premenopausal,
and 5-year tamoxifen was given in postmenopausal women.
Dose adjustments according to toxicity
Arm A: chemotherapy was given at full doses if neutrophil count
was X1.5 10
9l
 1, and platelet count was X100 10
9l
 1. Doses
were reduced by 50% if neutrophil count was o 1.5/10
9 and X1.0/
10
9l
 1, or platelet count was o100 10
9l
 1 and X75/10
9l
 1.I n
the case of grade X3 neutropenia, grade X2 thrombocytopenia, or
grade 41 nonhaematological toxicity the treatment was always
omitted. In the presence of grade 4 neutropenia, febrile
neutropenia, grade 4 thrombocytopenia, grade 4 anaemia, grade
3–4 nonhaematological toxicity (except for alopecia) doses were
reduced by 25% in the subsequent administrations. G-CSF was
allowed in the presence of grade 4 neutropenia of any duration, or
neutropenic fever, or if grade 3 neutropenia persisted for 2 weeks
after the scheduled time of recycling. The treatment was
definitively discontinued if chemotherapy could not be delivered
3 weeks after the scheduled time of recycling.
Arm B: chemotherapy was given at full doses for neutrophil
count X2000mm
 3, and platelet count X100000mm
 3.I f
neutrophil count was X1500mm
 3 persisted after a 1-week delay,
chemotherapy was delivered at 75% of the planned dose.
In the presence of grade 4 neutropenia, febrile neutropenia,
grade 4 thrombocytopenia, grade 4 anaemia, grade 3–4 non-
haematological toxicity (except for alopecia) doses were reduced to
75% in the subsequent administrations. G-CSF was allowed in the
presence of grade 4 neutropenia of any duration, or neutropenic
fever, or if grade 3 neutropenia persisted for 2 weeks after the
scheduled time of recycling. The treatment was definitively
discontinued if chemotherapy could not be delivered three weeks
after the scheduled time of recycling.
Toxicity and response evaluation criteria
Toxicity was assessed at the weekly visits and recorded using the
NCI-CTC version 3.0. Complete blood cell and WBC count were
performed once a week in all patients, and every other day in cases
of grade 4 haematological toxicity. Bidimensional echocardio-
graphy was performed on completion of treatment.
Clinical tumour response was assessed within 2 weeks from the
end of chemotherapy, and classified according to standard WHO
criteria (Miller et al, 1981). Clinical examination, mammography,
breast ultrasonography were performed to assess the regression of
the tumour in both breast and axilla. In addition, chest X-ray, and
abdomen ultrasonography were also performed, in order to
exclude the presence of distant metastases.
For pathologic assessment of response, the amount of residual
epithelial neoplastic cells in the tumour mass, and the location of
malignant component (invasive vs intraductal) were taken into
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saccount (Chevallier et al, 1993). Response in the breast was scored
as follows: class I (absence of residual malignant epithelial cells),
class II (persistence of only in situ residual malignant component),
class III (only focal invasive tumour residuals), class IV (no
substantial modifications in the tumour mass). Patients showing a
class I or II response in the breast, together with absence of axillary
involvement were considered as pCR.
End points and statistical considerations
The pCR rate was the main end point. We set as 5% the pCR rate
expected with the administration of epirubicin plus paclitaxel, and
we hypothesised a 10% increase with the PET regimen. To have an
80% power to demonstrate such a difference with an alpha error
o5%, at least 90 patients per arm were required (Casagrande
et al, 1978).
Progression-free survival (PFS) and overall survival (OS) were
also analysed. PFS was considered as the interval between
randomisation and documentation of progressive disease or
relapse (in surgically treated patients). Overall survival was
considered as the interval between randomisation and death by
any cause. All time-dependent curves were estimated by the
Kaplan Meier method (Kaplan and Meier, 1958). All patients were
included in the analysis of response and survival on an ‘intent to
treat basis’.
RESULTS
Demographics
Between May 1999 and November 2004, 200 consecutive women
with LABC were enrolled into this study. Table 1 outlines the main
patient characteristics. Overall, 136 patients had T4a-b-c disease,
while 47 women had inflammatory carcinoma, and 17 N2 disease.
Patients (144) had ductal carcinoma, and oestrogen or progester-
one receptors were positive in 110 and 103 patients, respectively.
Patients (43) were HER2þ.
Compliance to proposed treatment
Women (13) in the PET and seven women in ET arm did not
complete the planned number of chemotherapy cycles. Early
disease progression was the cause of treatment discontinuation
in three PET and four ET patients. The remaining early dis-
continuations were a consequence of severe toxicity or patient’s
refusal: in the PET arm, reasons for withdrawal were: severe
emesis in two cases, persistence of severe mucositis in one case,
severe peripheral neuropathy in two cases, severe fatigue in three
cases, and patient’s refusal in two cases. In the ET arm, severe
emesis (one case), and fatigue (two cases) forced the treatment
interruption.
A treatment delay due to persistence of haematological toxicity
or grade 41 non haematological toxicity on day of recycling
occurred in 18 and 11 patients in PET and ET arm, respectively. A
dose reduction was performed at least once in 35 PET and 21 ET
patients, respectively. In all, 71 PET and 83 ET patients actually
received X80% of the planned dose-intensity (Figure 1).
Response
All the 200 enrolled patients were included into the response
analysis on an ‘intent to treat basis’. Table 2 summarises clinical
response data. In the PET arm, 28 complete and 60 partial
responses were recorded at clinical restaging. An additional nine
patients showed a minor regression or stabilisation of the tumour.
In the ET arm, a clinically complete or partial response occurred in
19 and 59 patients, respectively. An additional 18 women showed a
minor response or no change.
According to receptor status, a clinical complete response
occurred in 19/40 (47.5%) ER negative and 8/53 (15%) ER positive
patients (one CR in a woman with hormone receptor status
unknown) in the PET arm. In the ET arm, a clinical complete
response occurred in 6/37 (16.2%) ER negative, and 12/57 (21%)
ER positive patients (one CR in a patient with unknown hormone
receptor status). Regarding HER2/neu status, 9/23 (40%) HER2þ
and 16/68 (23.6%) HER2  achieved a complete response in the
PET arm, as compared to 7/20 (35%) HER2þ and 10/68 (14.7%)
HER 2  in ET arm (Table 3).
Overall, 186 women (PET 94, ET 92) underwent surgery. Breast
sparing surgery was performed in a total of 37 patients (PET 23,
ET 14). Table 4 summarises the pathological response data. In all,
Table 1 Demographics
Characteristic
PET (100
patients)
ET (100
patients)
Total (200
patients)
Age
Median (range) 53 (27–73) 54 (30–72) 54 (27–73)
o 65/X65 52/48 49/51 101/99
Stage
T4 N0 12 14 26
T4 N1 79 78 157
Any T N2 9 8 17
Breast tumour
T4a-c/d 67/24 69/23 136/47
Histology
Ductal 71 73 144
Lobular 19 18 37
Mixed 4 4 8
Mucinous 3 2 5
Other 3 3 6
Grading
I 9 12 21
II 33 30 63
III 55 54 109
Unknown 3 4 7
Menopausal status
Pre-/postmenopausal 33/67 31/69 64/136
Hormone receptors status
ER: yes/no/unknown 53/40/7 57/37/6 110/77/13
PgR: yes/no/unknown 50/43/7 53/41/6 103/84/13
HER/neu status
Pos/neg/unknown 23/68/9 20/68/12 43/136/21
0
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Figure 1 Relative dose Intensity.
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s22 patients (PET 13, ET 9) showed absence of residual malignant
epithelial cells, either invasive or intraductal, in the breast
specimen. Only in situ residual tumour cells were found in
additional 14 women (PET 9, ET 5). Therefore, the pCR rate in the
breast was 22% in PET and 14% and ET arm, respectively. A pPR
in the breast (i.e., only focal invasive tumour residuals in the
removed breast tissue) was recorded in 38 PET and 26 ET patients,
respectively. Overall, 59 women (PET 35, ET 24) showed negative
axilla. Among the 141 patients with persistence of tumour in the
axilla, 60 (PET 33, ET 27) had one to three lymph nodes involved,
and 81 (PET 32, ET 49) four or more nodes.
In all, 22 patients (PET 16, ET 6) showed an absence of invasive
tumour in both breast and axilla; the pCR rate being 16 and 6% in
PET and ET arm, respectively (P¼0.02). In the PET arm, 11 pCRs
were observed among 40 ER negative tumours (27.5%) as
compared to four pCRs among 53 ER positive (7.5%), and one
among the seven with unknown hormone receptor status (14.3%).
In the ET arm, two pCRs were registered in the 37 ER negative
(5.4%) and four pCRs in the 57 ER positive tumours (7.1%). One
out of four women with ER positive tumour, achieving a pCR, had
negative PgR. All 11 ER negative tumours who achieved a pCR in
the PET arm, were PgR negative too. If a comparison between the
two arms is made taking into account the hormone receptor status,
the advantage of PET treatment is highly evident in ER negative
patients (PET 27.5 vs ET 5.4%; P¼0.026), while it did not appear
in the ER positive subgroup (PET 7.5 vs ET 7%) (Table 5).
Eight pCRs were observed in the 43 patients (18.6%) HER2/neu
positive, as compared to 11/136 (8%) HER2 negative cases (3/21
patients with HER2/neu unknown had a pCR). Also in this case the
superiority of the PET regimen was evident only in those patients
with HER2 positive tumour (31 vs 5%; P¼0.037) (Table 5).
After a median follow-up of 39 (range, 4–70) months, 70
patients had progressed or relapsed (PET 32, ET 38), and the
median PFS was 38.5 and 40.1 months in PET and ET arm,
respectively. Five-year projected PFS probability was 30 and 25%
for PET and ET, respectively (Figure 2).
Seven (PET 4, ET 3) of the 22 patients showing a pCR had
relapsed at the time of the present analysis (Figure 3).
Overall, 35 out of 77 patients with ER negative tumour (PET 16,
ET 19) had progression or relapse at the time of the present
analysis, as compared to 31 (PET 14, ET 17) out of 110 patients
with ER positive tumour; median PFS being 30.1 and 47.6 months,
respectively (Figure 4). Median PFS times in ER positive patients
were 38.2 months and 40.7 months for PET and ET, respectively;
while they were 32 and 34 months, respectively, in ER negative
patients (Figures 5–6). Four failures occurred in the 13 patients
with unknown receptor status.
Overall, 19 (PET 8, ET 11) of the 43 patients with HER2 positive
tumour had progressed or relapsed, median PFS being 25.5
months. A total of 43 (PET 20, ET 23) failures had occurred in the
136 HER2 negative patients, median PFS being 44.7 months
(Figure 7).
Overall, 26 deaths (PET 10, ET 16) had occurred at the time
of the present analysis. Median survival had not been reached in
both arms.
Toxicity
A total of 1122 PET courses and 386 ET courses were delivered and
analysed for toxicity. No toxic deaths were observed in either arms.
Table 3 Complete response according to hormone receptors and her/
neu status
PET no. (%) ET no. (%) Total no. (%)
Hormone receptors
ER  19/40 (47.5) Po0.05 6/37 (16.2) 25/77 (32.5)
ER+ 8/53 (15) P¼NS 12/57 (21) 20/110 (18)
Unknown 1/7 (14.5) 1/6 (16.5) 2/13 (15.4)
HER/neu
+ 9/23 (40) P¼NS 7/20 (35) 16/43 (37.2)
  16/68 (23.6) P¼NS 10/68 (14.7) 26/136 (19)
Unknown 3/9 (33.3) 2/12 (16.7) 5/21 (24)
Table 4 Pathological assessment according to treatment arm
PET no. (%) ET no. (%) Total no. (%)
Breast
Class I 13 (13) P¼NS 9 (9) 22 (11)
Class II 9 (9) P¼NS 5 (5) 14 (7)
Class III 38 (38) 26 (26) 64 (32)
Class IV 40 (40) 60 (60) 100 (50)
Axilla
N0 35 (35) 24 (24) 59 (29.5)
N1–3 33 (33) 27 (27) 60 (30)
N 43 32 (32) 49 (49) 81 (40.5)
pCR (class I+II and N0) 16 (16) P¼0.02 6 (6) 22 (11)
Table 5 Pathological complete response according to pretreatment
features
PET no. pCR (%) ET no. pCR (%) Total no. pCR (%)
ER  11/40 (27.7)* 2/37 (5.4) 13/77 (17)
ER+ 4/53 (7.5) 4/57 (7.1) 8/110 (7)
Unknown 1/7 (14) 0/6 1/13 (8)
HER pos 7/23 (31)
# 1/20 (5) 8/43 (18.6)
HER neg 7/68 (10) 4/68 (6) 11/136 (8)
Unknown 2/9 (22) 1/12 (8) 3/21 (14)
*PET vs ET: P¼0.026.
#PET vs ET; P¼0.037.
Table 2 Clinical response according to treatment ARM
PET no. (%) ET no. (%) Total no. (%)
Complete 28 (28) P¼NS 19 (19) 47 (23.5)
Partial 60 (60) 59 (59) 119 (59.5)
MR/NC 9 (9) 18 (18) 27 (13.5)
PD 3 (3) 4 (4) 7 (3.5)
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Figure 2 Progression free survival.
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sTable 6 shows the number of patients in each arm who experienced
at least one grade X3 toxicity.
Haematological toxicity was not substantially different in the
two arms, except for anaemia. Overall 45 patients in PET and 38 in
ET arm experienced a grade X3 neutropenia. Grade 4 occurred
in 17 and 18 cases, respectively. Neutropenic fever was observed in
three PET and four ET patients. Severe thrombocytopenia was
almost anecdotic, grade 3 or 4 occurring in only six patients (four
PET and two ET). Only one case of grade 4 thrombocytopenia was
recorded, occurring in the PET arm. Severe anaemia occurred in
one ET patient, as compared to 13 (13%) PET patients.
Overall, severe gastrointestinal toxicity and fatigue were also
more frequent in the PET arm. They caused early chemotherapy
discontinuation in a total of eight patients (five PET and three ET).
Severe emesis, loss of appetite, and diarrhoea occurred in 10, 13,
and 15% of PET as compared to 4, 5, and 2% of ET arm. Severe
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Figure 4 PFS according to ER status.
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Table 6 Who grade 3–4 toxicity in the two arms
PET (100) ET (100)
No. of patients (%) No. of patients (%)
Neutropenia 45 (45) 38 (38)
Sepsis 3 (3) 4 (4)
Thrombocytopenia 4 (4) 2 (2)
Anaemia 13 (13) 1 (1)
Nausea 9 (9) 6 (6)
Vomiting 6 (6) 4 (4)
Loss of appetite 13 (10) 5 (5)
Diarrhoea 15 (15) 2 (2)
Mucositis 12 (12) 1 (1)
Neurotoxicity 3 (3) 0
Renal 0 0
Liver 0 0
Fatigue 11 (11) 2 (2)
Cardiac toxicity
o 50% LVEF 5 (5) 3 (3)
Congestive failure 0 0
Skin toxicity 3 (3) 0
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sfatigue occurred in 11 (11%) patients of PET and two (2%) patients
of ET arm.
Neurotoxicity and mucositis and were also common side effects
in both arms. Overall, 34 (34%) PET and 16 (16%) ET patients
complained of sensory neuropathy, but it was severe in only three
patients of PET arm, and in two cases it caused treatment
discontinuation. Severe mucositis was recorded in 12 PET patients,
and in one case it caused the definitive treatment discontinuation.
Only one patient of the ET arm experienced severe mucositis.
Renal, liver and cardiac toxicity were very uncommon. There were
no cases of severe functional impairment of these organs. Five PET
and three ET patients had a LVEF decrease below 50%. In all but
one patient (treated with PET), LVEF returned within the normal
range. No patients showed clinical signs of congestive heart failure.
DISCUSSION
In the present randomised study, we aimed at evaluating whether
12 weekly preoperative cycles of PET with G-CSF support could
improve the pCR rate achievable in patients with LABC (stage IIIB)
in comparison with ET tri-weekly administration.
Our results seem to suggest that the PET weekly treatment is
more effective than the tri-weekly ET regimen in producing a pCR.
Indeed, the chance of achieving a complete clearance of the
tumour in both breast and axilla in the PET arm was more than
twice that of the ET arm.
The rate of pCR obtained in the present study with the standard
treatment (ET) does not seem to be underestimated. In the Milan
NCI experience, the use of neoadjuvant doxorubicin-paclitaxel
combination gave a 7% pCR rate in a study population including
41 II/IIIA and 38 IIIB patients (Moliterni et al, 1997). Canadian
authors recently reported a 9% pCR rate in 49 patients with locally
advanced disease, 60% of whom had stage IIB and IIIA. They also
remarked that, depending on the definition of pCR used, the range
of pCR varied from 4.2% (using definition from Chevallier) to
10.6% (using that of NSABP-27 study) (Dent et al, 2005).
The present study was sized setting the pCR rate as the target
end point. Of course, the achievement of a complete eradication
of the tumour in both breast and axilla may be considered a
meaningful end point only if it is associated with a substantial
improvement of the long-term disease-free survival.
At the time of the present analysis, the number of observed
failures (70 progressions or relapses) is too low to even allow us to
speculate about the impact that this new regimen may have on
prognosis of these patients. Moreover, given the very small rate of
patients who are expected to have a substantial DFS gain (16 vs 6%
pCRs), a much larger study population would be required to
statistically detect such a gain.
Analysis of our data strongly suggests that this dose dense
approach may be superior only in some subsets of patients and not
in the whole population. Indeed, an impressive increase of the pCR
rate with the PET regimen was obtained in patients with ER
negative (27.5 vs 5.4%) and/or HER2/neu positive tumour (31 vs
5%), while the activity of the two regimens was comparable in
patients with ER positive (7.5 vs 7%) and/or HER2/neu negative
tumour (10 vs 6%). The modest effect of the primary chemother-
apy in ER positive tumours was noted by other investigators, who
recently reported a much higher pCR rate with chemotherapy in
ER/PgR negative patients (Faneyete et al, 2003; Colleoni et al, 2004;
Ring et al, 2004; Gianni et al, 2005) and seems to suggest that
aggressive chemotherapy should not be advisable in hormone-
sensitive tumours. In a previous phase II study, testing the PET
regimen in patients with large operable breast cancer, we observed
a pCR rate in 66% in ER negative patients as compared to 14% in
ER positive (Frasci et al, 2005).
In the present study, seven out of 22 pCRs relapsed. This relapse
rate looks similar to that of the total population. However, in the
ER/PgR negative group 4/13 pCRs relapsed as compared to 31/64
non-pCRs. Moreover, three out of four relapsing pCRs were also
HER2 positive, and in two cases brain was the first site of relapse.
These findings suggest that chemotherapy alone is not enough in
the management of HER2 positive patients, who might benefit of a
prolonged trastuzumab treatment.
On the other hand, the impressive increase of the pCR rate in
ER/PgR negative tumours with the weekly treatment could
represent a simple ‘optical illusion’ if not followed by a substantial
advantage in long-term disease-free survival of patients. An occult
metastatic spread may derive from malignant cell clones, which
have developed an acquired resistance to cytotoxic drugs, and are
therefore less sensitive to the induction chemotherapy than the
primary tumour. At the Mount Sinai Medical Center 144 patients
with LABC treated with neoadjuvant chemotherapy were reviewed
to evaluate the prognostic impact of chemotherapy-induced
histological changes. Little evidence in favour of predictivity of
pathological response was found (Gajdos et al, 2002). In another
recent report from the US NCI, 107 patients with stage III breast
cancer were treated with a multimodality approach. Pathologic
response was not associated with improved survival for stage
IIIA and inflammatory breast cancer patients (Low et al, 2004).
In an MDACC retrospective analysis conducted on 372 women
with LABC, the DFS and OS of the pCRs group were significantly
better than those of the other group; however, investigators
remarked that a pCR did not eliminate the risk of recurrence
(Kuerer et al, 1999).
In the present study, a reduction of the risk of relapse with the
PET regimen becomes evident after 3 years in ER/PgR negative
patients, and is maintained beyond 5 years. Given the small study
population, it is clear that such a difference cannot be statistically
significant, even with a more mature follow-up. A new randomised
trial, specifically targeted to ER/PgR negative patients, with an
adequate sample size is required to address this issue.
The impressive increase of the pCR rate in HER2/neu positive
patients with the weekly treatment also deserves some considera-
tions. There are several possible factors responsible for the
observed better tumour shrinkage in the PET arm. Firstly, the
increase of the epirubicin dose intensity, as previously reported by
French authors (Petit et al, 2001).
The adoption of a weekly paclitaxel schedule might also have a
role. In the CALGB 9840 trial, (Seidman et al, 2004) weekly
paclitaxel significantly improved ORR and survival of metastatic
breast cancer patients, when compared with standard every 3
weeks paclitaxel. However, in patients with HER2/neu normal
tumour, the weekly administration failed to produce a significant
gain in both ORR and survival.
In spite of the very impressive pCR rate observed in HER2
positive patients, the DFS outcome was disappointing in this
group, the risk of relapse being relevant even in pCRs. Of course,
the discovery of a drug specifically targeting HER2/neu over-
expressing tumour cells has deeply modified the therapeutic
strategy in this subset of patients. The capability of trastuzumab in
improving the prognosis of patients with metastatic disease is well
established (Slamon et al, 2001). Preliminary reports also suggest
that the addition of trastuzumab to a standard anthracycline-
taxane combination can dramatically increase the pCR rate in
women with operable breast cancer (Buzdar et al, 2005).
The addition of trastuzumab to a dose dense aggressive
chemotherapy, like PET, could result in a further substantial
increment of the pCR rate. Moreover, it could substantially
increase the probability of obtaining the eradication of the distant
micrometastases, as suggested by the results of several large
randomised trials (Piccart-Gebhart et al, 2005; Romond et al,
2005).
A final consideration on the toxicity profiles of the two regimens
deserves to be made. Although our dose dense approach did not
cause any life-threatening toxicity, it produced a substantial
increase of severe side effects, which may negatively impact on
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sthe quality of life of patients. Severe anaemia was significantly
more frequent in the PET arm, and it resulted in a substantially
higher proportion of patients complaining about severe fatigue.
PET treatment was also associated with more severe nonhaema-
tological toxicity. In particular, diarrhoea, peripheral neuropathy
and mucositis occurred more frequently in the PET arm, being the
main causes of patient’s discomfort. In view of that, an accurate
selection of patients who more likely can benefit of this approach
is mandatory in the next future.
In conclusion, a 3-month preoperative treatment with weekly
PET plus G-CSF support yields a significantly higher pathological
complete response rate in women with LABC compared with four
tri-weekly ET cycles. The superiority of the PET regimen was
limited to hormone-receptor negative or HER2/neu overexpressing
tumours. PET treatment was associated with a substantial increase
in nonhaematological toxicity. A longer follow-up is needed to
better evaluate the impact of this new approach on failure-free and
OS. However, such a dose-dense approach is not recommended in
women with ER/PgR positive LABC. Adequately powered,
randomised trials are required to evaluate whether this approach
can significantly improve prognosis of ER negative and/or HER2
positive LABC patients.
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